Shuttle Pharma Finalizes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine
Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.
Clinical Trials | 29/10/2024 | By Aishwarya
Unravel Biosciences and PECET to Conduct Clinical Trials of RVL-001 in Rett Syndrome in Colombia
Unravel's proprietary BioNAV drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS.
Clinical Trials | 25/10/2024 | By Aishwarya
Evergreen Theragnostics Opens Phase II Small Cell Lung Cancer Clinical Trial in EU
The CCK2-VIEW trial uses 68Ga-EVG321, a peptide-based Radioligand imaging agent administered to patients with small cell lung cancer.
Clinical Trials | 18/10/2024 | By Aishwarya
Eximia Research Acquires Integrated Clinical Trial Services
With this expansion into Iowa, this partnership marks another significant milestone in Eximia's mission to broaden access to cutting-edge clinical trials and innovative healthcare solutions across the nation.
Clinical Trials | 17/10/2024 | By Aishwarya
GBI and Allterum to Manufacture Therapeutic Antibody for Clinical Trials
With this collaboration, GBI will leverage their extensive expertise in manufacturing complex biologics to ensure the high-quality production of 4A10 for Phase 1/2a clinical trials.
Clinical Trials | 08/10/2024 | By Aishwarya
CD Biopharma Receives FDA Clearance for Phase I Clinical Trial of CD-001
CD-001, the company's clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform.
Clinical Trials | 20/09/2024 | By Aishwarya
GC Biopharma, Hanmi Pharma Secure IND Clearance for Phase 1/2 Clinical Trial
LA-GLA is an innovative new drug for the treatment of Fabry disease as the world's first once-monthly subcutaneous treatment, which is being co-developed by GC Biopharma and Hanmi Pharmaceutical.
Clinical Trials | 03/09/2024 | By Aishwarya
Sanofi Reveals Positive Results of Tolebrutinib in HERCULES Phase 3 Study
In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded disability status scale (EDSS) score between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months.
Clinical Trials | 03/09/2024 | By Aishwarya
Grit Biotechnology Secures IND Clearance for GT201 from US FDA
GT201, an advanced genetically engineered TIL product developed by Grit Biotechnology's platforms StemTexp and StaViral, boosts T cell survival and function by expressing a vital membrane-bound cytokine complex.
Clinical Trials | 02/09/2024 | By Aishwarya
Mabwell Gets CDE Approval to Initiate Phase III Clinical Trial of 9MW2821
9MW2821 is a novel Nectin-4-targeting ADC independently developed by Mabwell, and it is the first of its kind in China to initiate clinical trials on the same target, with more than 400 subjects enrolled in the clinical studies for multiple indications.
Clinical Trials | 27/08/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy